Parabilis filed for an initial public offering shortly after signing an up-to-$2.3 billion strategic research collaboration with Regeneron. The company’s Helicon peptide platform targets historically undruggable protein interactions via antibody–Helicon conjugates, with Regeneron agreeing to purchase roughly $75 million of Parabilis shares in a concurrent private placement at 90% of the IPO price. Parabilis also pointed to continued clinical development for zolucatetide (FOG-001), including dose expansion in desmoid tumors and a planned Phase III registrational trial, along with expansion efforts across familial adenomatous polyposis and additional tumor indications. The IPO filing underscores how companies with validated platform science are positioning for liquidity and scale amid improved biotech public-market conditions. For investors and portfolio managers, the key read-through is the pairing of a major strategic partner with a near-term capital plan—an approach designed to de-risk development timelines and broaden pipeline optionality.